A total of 905 patients with HER2-low expression or HER2-negative breast cancer who received NACT were identified (mean age 49.2 ± 9.5 years (range 20–75 years)) and 119 patients (13.1%) who achieved pCR after NACT. Here, ERBB2 is linked to breast cancer.